Entity

Time filter

Source Type

Yamagata-shi, Japan

Kawai M.,Kawai ENT Clinic | Ohta N.,Yamagata City Hospital Saiseikan
Practica Oto-Rhino-Laryngologica | Year: 2015

Beclometasone (product name: Salcoat®) for oral spray is a powder formulation containing a large amount of a mucosal-adhesive base material (hydroxypropyl cellulose: HPC), which allows the drug to be retained longer at the local site. When the product is sprayed on the affected site with a dedicated small sprayer (pubriser®), the HPC gelates by absorbing moisture on the mucosal surface and adheres to the mucosa. As a result, it remains at the affected site for a prolonged period of time and thereby also releases the active ingredient (steroid) locally for a prolonged period of time. Treatment with Salcoat® nasal spray (one puff in each nostril, twice daily) was given to 10 patients with nasal polyps associated with allergic rhinitis who showed no improvement with conservative treatment for one year or longer. Subjective improvement in the feeling of nasal congestion was observed in 7 cases and the nasal polyps shrank in 5 cases. Treatment with Salcoat® was prematurely discontinued in one patient because nasal congestion occurred immediately after the formulation was sprayed, due to gelation of the drug. None of the patients showed any signs of mycosis. Source


Okano S.,Research Laboratory for Molecular Genetics | Hayasaka K.,Yamagata University | Igarashi M.,Yamagata City Hospital Saiseikan | Togashi Y.,Research Laboratory for Molecular Genetics | Nakajima O.,Research Laboratory for Molecular Genetics
Journal of Diabetes Investigation | Year: 2013

Aims/Introduction: In earlier reports, we described that transgenic (Tg) mice ubiquitously expressing cryptochrome1 (CRY1) with a mutation in cysteine414 (CRY1-AP Tg mice) show an early-onset insulin-secretory defect of diabetes mellitus resembling human maturity-onset diabetes of the young (MODY). To clarify the yet undiscovered molecular pathogenesis of diabetes mellitus in which the mutant of CRY1 is involved, we examined age-dependent characteristics of islets of CRY1-AP Tg mice. Materials and Methods: Immunohistochemical analyses of islets were carried out for 2-, 4- and 19-week-old mice. Insulin contents in the pancreas and glucose-stimulated insulin secretion of isolated islets of mice were measured at 4 weeks. Real-time polymerase chain reaction analyses using pancreases of mice at 4 and 21 weeks-of-age were carried out. Results: Already at a young stage, the proliferation of β-cells was reduced in CRY1-AP Tg mice. Insulin contents and the levels of glucose-stimulated insulin secretion were lower than those of wild-type controls in CRY1-AP Tg mice at the young stage. The expression of insulin and glucose-sensing genes was reduced at the young stage. At the mature stage, altered distribution and hyperplasia of α-cells were observed in the islets of CRY1-AP Tg mice. Conclusions: Architectural abnormality in islets progressed with age in CRY1-AP Tg mice. The reduced expression of insulin and glucose-sensing genes, along with the lowered proliferation of β-cells from an early stage, is a possible primary cause of early-onset insulin-secretory defect in CRY1-AP Tg mice. Our results suggest that CRY1 is crucial for the maintenance of β-cell function. © 2013 Asian Association for the Study of Diabetes and Wiley Publishing Asia Pty Ltd. Source


Ichikawa S.,Yamagata City Hospital Saiseikan
Journal of clinical and experimental hematopathology : JCEH | Year: 2012

A 71-year-old woman presented with massive splenomegaly. Open splenectomy was performed, and the diagnosis of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), was made, with a characteristic immunophenotype of CD3(+), CD4(-), CD8(-), T-cell receptor (TCR)αβ(+), and TCRγδ(-). After splenectomy, she suffered abrupt exacerbation of the lymphoma with disseminated intravascular coagulation and enteropathy. Although chemotherapy was started, her medical condition did not improve and she died a week later. Postmortem reevaluation of the pathological specimen confirmed her diagnosis as CD20(+) PTCL-NOS. Although it is a rare disease entity, CD20(+) T-cell lymphoma can demonstrate aggressive clinical behavior. Source


Minematsu K.,Japan National Cardiovascular Center Research Institute | Toyoda K.,Japan National Cardiovascular Center Research Institute | Hirano T.,Oita University | Kimura K.,Kawasaki Medical School | And 13 more authors.
Journal of Stroke and Cerebrovascular Diseases | Year: 2013

In Japan, intravenous alteplase, a recombinant tissue-type plasminogen activator (rt-PA), was approved for an indication of ischemic stroke in 2005 on the basis of the results of a clinical trial with a unique dose of the drug (0.6 mg/kg). The Japan Stroke Society published the guidelines for intravenous application of rt-PA and organized training sessions for proper use all over Japan in an effort to promote the safe, widespread use of intravenous alteplase. Seven years following its approval, clinical experience with intravenous alteplase has accumulated, additional evidence of intravenous alteplase has been found in Japan and overseas, and the medical environment has substantially changed, including approvals for new drugs and medical devices. Notably, the use of alteplase in the extended therapeutic time window (within 4.5 hours of symptom onset) became covered by insurance in Japan in August 2012. To address these changing situations, we have decided to prepare the revised guidelines. In preparing the second edition, we took care to make its contents more practical by emphasizing information needed in clinical practice. While the first edition was developed with emphasis on safety in light of limited clinical experience with intravenous alteplase in Japan in 2005, this second edition is a substantial revision of the first edition mainly in terms of eligibility criteria, on the basis of accumulated evidence and the clinical experience. © 2013 by National Stroke Association. Source


Shimizu Y.,Yamagata City Hospital Saiseikan | Abiko C.,Yamagata Prefectural Institute of Public Health | Ikeda T.,Yamagata Prefectural Institute of Public Health | Mizuta K.,Yamagata Prefectural Institute of Public Health | Matsuzaki Y.,Yamagata University
Pediatric Infectious Disease Journal | Year: 2015

A 6-month prospective study in a hospital setting detected influenza C virus and human metapneumovirus in 10.0% (29/289) and 16.6% (48/289), respectively, of children hospitalized with lower respiratory tract illness. Influenza C virus infection had a similar rate of pneumonia (53.3% vs. 57.1%), significantly lower frequency of wheezing (13.3% vs. 68.6%) and higher values of white blood cell and C-reactive protein than human metapneumovirus infection. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. Source

Discover hidden collaborations